clinical trial · NCT07196111
BAFFR CAR-T Treatment for Relapsed/Refractory B-cell Tumors
Guangzhou Bio-gene Technology Co., Ltd·early phase1·not yet recruiting·n = 12
B Acute Lymphoblastic Leukemia/LymphomaBAFFR CAR-T
brief summary
This study is a single-arm, multicenter clinical trial of dose escalation and dose expansion.
started
Oct 10, 2025
primary completion
Oct 9, 2028
completion
Dec 9, 2028
last updated
Sep 29, 2025
detailed description
This study is a single-arm, mult-center clinical trial of dose escalation and dose expansion, primarily aimed at evaluating the safety, tolerability, and preliminary efficacy of BAFFR CAR-T cell infusion in subjects with relapsed/refractory B-cell tumors.
official title
Evaluation of the Safety and Efficacy of BAFFR CAR-T Therapy in Clinical Studies for Recurrent/Refractory B Cell Tumors.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol